MLTX
MoonLake Immunotherapeutics
NASDAQ: MLTX · HEALTHCARE · BIOTECHNOLOGY
$16.38
+1.68% today
Updated 2026-04-30
Market cap
$1.23B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.53
Dividend yield
—
52W range
$6 – $63
Volume
1.1M
MoonLake Immunotherapeutics (MLTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | $4971.00 | $12358.00 | $13158.00 | $1.38M | $2.62M |
| Gross profit | — | $-4971.00 | $-12358.00 | $-13158.00 | $-1.38M | $-2.62M |
| Gross margin | — | — | — | — | — | — |
| R&D | — | $35.52M | $42.05M | $31.80M | $112.77M | $202.86M |
| SG&A | — | $4.57M | $23.01M | $22.32M | $30.32M | $41.97M |
| Operating income | $-105755.00 | $-4.57M | $-65.06M | $-54.12M | $-143.09M | $-244.83M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-90838.00 | $-4.57M | $-65.05M | $-53.75M | $-141.71M | $-219.85M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-90838.00 | $-4.57M | $-65.06M | $-54.12M | $-143.09M | $-222.46M |
| Interest expense | — | $0.00 | $591732.00 | $0.00 | $0.00 | $7.25M |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-90838.00 | $-4.54M | $-64.51M | $-36.01M | $-118.94M | $-227.32M |
| Net income growth (YoY) | — | -4900.8% | -1320.0% | +44.2% | -230.3% | -91.1% |
| Profit margin | — | — | — | — | — | — |